Open an account

Zomedica

ZOMDF · NYSE American

$0.0779−$0.0011 (−1.39%)TodayMarket closed ·
Prev close $0.079

About ZOMDF

Zomedica Corp. engages in the discovery, development, and commercialization of pharmaceuticals for companion animals, including dogs, cats, and horses. The company is headquartered in Ann Arbor, Michigan and currently employs 141 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice economics. Its Diagnostics segment consists of TRUFORMA, VETGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi Loop and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field therapy.

Employees
141
Headquarters
Ann Arbor, Michigan
Listed
Oct 28, 2013
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
zomedica.com

ZOMDF key statistics

Market cap
86.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
865.92K
Volume
578.82K
Open price
$0.078
High today
$0.0829
Low today
$0.075
52 Week high
$0.158
52 Week low
$0.0625

Zomedica (ZOMDF) at a glance

As of Oct 20, 2026, Zomedica (ZOMDF) shares are priced at $0.0779, giving the company a market cap of 86.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.075 and $0.0829. The current price is 3.9% above the day's low and 6.0% below its high.

Volume so far is 578.82K shares, below the average of 865.92K shares a day.

Over the past year Zomedica has ranged from $0.0625 to $0.158, and now sits 16% of the way up that range.

Zomedica met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q1 FY25 it reported -$0.07 per share against an estimate of -$0.0072.

ZOMDF earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q2 FY23: reported -$0.005 per share against an estimate of $0.00
  2. Q3 FY23: reported -$0.001 per share against an estimate of $0.00
  3. Q4 FY23: reported -$0.01 per share against an estimate of $0.00
  4. Q1 FY24: reported -$0.01 per share against an estimate of $0.00
  5. Q2 FY24: reported $0.00 per share against an estimate of $0.00
  6. Q3 FY24: reported -$0.01 per share against an estimate of $0.00
  7. Q4 FY24: reported -$0.01 per share against an estimate of -$0.0072
  8. Q1 FY25: reported -$0.07 per share against an estimate of -$0.0072

ZOMDF news

  • Press releaseACCESS Newswire

    Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption

  • Press releaseACCESS Newswire

    Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices

  • Press releaseACCESS Newswire

    Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue

  • Press releaseACCESS Newswire

    Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform

  • Press releaseACCESS Newswire

    Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation

  • Press releaseACCESS Newswire

    Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

  • Press releaseACCESS Newswire

    Zomedica Launches the PulseVet Acoustic Muffler(TM) Accessory for PulseVet(R) Shock Wave System

  • Press releaseACCESS Newswire

    Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic

Similar companies

Companies in the same industry as Zomedica

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.